Research progress of comprehensive treatment for tuberculosis

doi:10.19983/j.issn.2096-8493.20230112

Abstract

Abstract:

Tuberculosis is a chronic infectious disease caused by the infection of Mycobacterium tuberculosis complex. Although the success of BCG vaccine and effective anti-tuberculosis drugs has provided effective means of tuberculosis prevention and treatment, it is still quite challenging to cure tuberculosis completely with the continuous flow of population, and continuous emergence of HIV infection, usage of immunosuppressive drugs for special diseases and drug-resistant tuberculosis, especially for that the prevalence of COVID-19 since the end of 2019 has set back the epidemic control of tuberculosis for at least 5-8 years. Curing tuberculosis patients thoroughly is still the key measure to cut off the transmission of Mycobacterium tuberculosis and eliminate disease transmission. On the basis of anti-tuberculosis chemotherapy, combined with comprehensive treatment methods such as surgical treatment, interventional therapy, immunotherapy, nutritional therapy, traditional Chinese medicine treatment, psychological therapy, and rehabilitation therapy, it is beneficial to improve the patient’s cure rate and reduce adverse reactions. Clinicians need to comprehensively evaluate the specific condition of patients and choose individualized comprehensive treatment plans in a targeted manner to achieve the optimal treatment effect. This article reviews the research progress of tuberculosis comprehensive treatment in recent years.

Key words: Tuberculosis, Mycobacterium tuberculosis, Drug resistance,multiple, Antitubercular agents

CLC Number:

Liang Chen, Tang Shenjie, Lin Minggui. Research progress of comprehensive treatment for tuberculosis[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(1): 70-80. doi: 10.19983/j.issn.2096-8493.20230112

References 150

[1]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	Jeong Y, Min J. Impact of COVID-19 Pandemic on Tuberculosis Preventive Services and Their Post-Pandemic Recovery Strategies: A Rapid Review of Literature. J Korean Med Sci, 2023, 38(5): e43. doi:10.3346/jkms.2023.38.e43. pmid: 36747365
[3]	Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int J Mol Sci, 2023, 24(6):5202. doi:10.3390/ijms24065202.
[4]	Peloquin CA, Davies GR. The Treatment of Tuberculosis. Clin Pharmacol Ther, 2021, 110(6): 1455-1466. doi:10.1002/cpt.2261. pmid: 33837535
[5]	Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov, 2013, 12(5): 388-404. doi:10.1038/nrd4001. pmid: 23629506
[6]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi:10.1056/NEJMoa2033400.
[7]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[8]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10): 733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
[9]	World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2022.
[10]	Chiang CY, Centis R, Migliori GB. Drug-resistant tuberculosis: past, present, future. Respirology, 2010, 15(3): 413-432. doi:10.1111/j.1440-1843.2010.01738.x.
[11]	Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc, 2019, 66(4): 520-532. doi:10.1016/j.ijtb.2019.11.005. pmid: 31813444
[12]	Bermingham WH, Bhogal R, Arudi Nagarajan S, et al. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs. Clin Exp Allergy, 2022, 52(3): 375-386. doi:10.1111/cea.14084.
[13]	Gils T, Lynen L, de Jong BC, et al. Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect, 2022, 28(1): 31-42. doi:10.1016/j.cmi.2021.08.007.
[14]	Holt E. A new treatment for drug-resistant tuberculosis in Ukraine. Lancet Infect Dis, 2022, 22(1): 23. doi:10.1016/S1473-3099(21)00772-6. pmid: 34953550
[15]	Mulder C, Rupert S, Setiawan E, et al. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Glob Health, 2022, 7(1):e007182. doi:10.1136/bmjgh-2021-007182.
[16]	Qiao J, Yang L, Feng J, et al. Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for patients with postoperative multidrug-resistant spinal tuberculosis. Int J Infect Dis, 2022, 118:264-269. doi:10.1016/j.ijid.2022.03.020. pmid: 35339715
[17]	Yao R, Wang B, Fu L, et al. Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis. Microbiol Spectr, 2022, 10(1): e0247721. doi:10.1128/spectrum.02477-21.
[18]	Huang Z, Luo W, Xu D, et al. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorg Med Chem Lett, 2022, 71:128824. doi:10.1016/j.bmcl.2022.128824.
[19]	刘海婷, 付雷, 王彬, 等. 抗结核新药吡法齐明组合用药的体外及小鼠体内抗结核活性研究. 中华结核和呼吸杂志, 2022, 45(6): 560-566. doi:10.3760/cma.j.cn112147-20211008-00697.
[20]	Luo W, Huang Z, Xu D, et al. Discovery and preclinical evalua-tions of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorg Med Chem Lett, 2022, 72:128871. doi:10.1016/j.bmcl.2022.128871.
[21]	中华医学会结核病学分会. 中国耐多药和利福平耐药肺结核外科治疗专家共识(2022年版). 中华结核和呼吸杂志, 2023, 46(2): 111-120. doi:10.3760/cma.j.cn112147-20221222-00986.
[22]	Pontali E, Matteelli A, D’Ambrosio L, et al. Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Rev Anti Infect Ther, 2012, 10(10): 1109-1115. doi:10.1586/eri.12.108. pmid: 23199397
[23]	Madansein R, Parida S, Padayatchi N, et al. Surgical treatment of complications of pulmonary tuberculosis, including drug-resistant tuberculosis. Int J Infect Dis, 2015, 32:61-67. doi:10.1016/j.ijid.2015.01.019. pmid: 25809758
[24]	Kempker RR, Vashakidze S, Solomonia N, et al. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis, 2012, 12(2): 157-166. doi:10.1016/S1473-3099(11)70244-4. pmid: 22281142
[25]	Man MA, Nicolau D. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur J Cardiothorac Surg, 2012, 42(1): e9-12. doi:10.1093/ejcts/ezs215.
[26]	Gegia M, Kalandadze I, Kempker RR, et al. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis, 2012, 16(5): e391-396. doi:10.1016/j.ijid.2011.12.018.
[27]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment-Drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[28]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
[29]	Giller DB, Giller GV, Giller BD, et al. Case of Video-Assisted Thoracoplasty Application in Pulmonary Tuberculosis Treatment. Ann Thorac Surg, 2020, 109(2): e95-e98. doi:10.1016/j.athoracsur.2019.04.112.
[30]	Xu HB, Jiang RH, Li L. Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. J Antimicrob Chemother, 2011, 66(8): 1687-1695. doi:10.1093/jac/dkr210.
[31]	Xie B, Yang Y, He W, et al. Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai. Interact Cardiovasc Thorac Surg, 2013, 17(3): 455-459. doi:10.1093/icvts/ivt251.
[32]	Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis, 2013, 17(1): 6-16. doi:10.5588/ijtld.12.0198. pmid: 23232000
[33]	Peng AZ, Yang A, Li SJ, et al. Incidence, laboratory diagnosis and predictors of tracheobronchial tuberculosis in patients with pulmonary tuberculosis in Chongqing, China. Exp Ther Med, 2020, 20(6): 174. doi:10.3892/etm.2020.9304.
[34]	Su Z, Cheng Y, Wu Z, et al. Incidence and Predictors of Tracheobronchial Tuberculosis in Pulmonary Tuberculosis: A Multicentre, Large-Scale and Prospective Study in Southern China. Respiration, 2019, 97(2): 153-159. doi:10.1159/000492335. pmid: 30205411
[35]	古丽巴哈尔·阿不拉合买提, 玛依拉·卡德尔, 卡力曼·阿不都热合曼, 等. 支气管镜介入治疗肺结核合并支气管结核老年患者的病灶吸收率和安全性. 中国内镜杂志, 2021, 27(9): 69-74. doi:10.12235/E20200453.
[36]	Jung SS, Park HS, Kim JO, et al. Incidence and clinical predictors of endobronchial tuberculosis in patients with pulmonary tuberculosis. Respirology, 2015, 20(3): 488-495. doi:10.1111/resp.12474.
[37]	Kashyap S, Solanki A. Challenges in endobronchial tuberculosis: from diagnosis to management. Pulm Med, 2014, 2014:594806. doi:10.1155/2014/594806.
[38]	Xue Q, Wang N, Xue X, et al. Endobronchial tuberculosis: an overview. Eur J Clin Microbiol Infect Dis, 2011, 30(9): 1039-1044. doi:10.1007/s10096-011-1205-2.
[39]	唐神结, 李亮, 杜建. 中国结核病年鉴2022. 北京: 中华医学电子音像出版社, 2023.
[40]	刁丽娟. 气管支气管结核导致腔内阻塞行电子支气管镜下冷冻治疗的效果探析. 临床研究, 2022, 30(7): 32-35. doi:10.12385/j.issn.2096-1278(2022)07-0032-04.
[41]	周海波, 饶莉. 电子支气管镜下冷冻治疗支气管结核的疗效研究. 中国医疗器械信息, 2023, 29(13): 117-119. doi:10.3969/j.issn.1006-6586.2023.13.035.
[42]	赵光强, 王彬, 陈运庭, 等. 电子支气管镜下冷冻介入治疗支气管结核的临床疗效及安全性评价. 结核与肺部疾病杂志, 2022, 3(1): 14-18. doi:10.19983/j.issn.2096-8493.20210098.
[43]	Zhou ZQ, Feng JX, Chen Y, et al. Self-expanding covered metallic stents as a transition to silicone stent implantation in management of severe post-tuberculosis bronchial stenosis. Ther Adv Respir Dis, 2021, 15:17534666211019564. doi:10.1177/17534666211019564.
[44]	Lin LQ, Chen DF, Wu HK, et al. Long-term efficacy and safety of the Dumon stent for treatment of benign airway stenosis. Ther Adv Respir Dis, 2023, 17:17534666231181269. doi:10.1177/17534666231181269.
[45]	中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行). 中华结核和呼吸杂志, 2012, 35(8): 581-587. doi:10.3760/cma.j.issn.1001-0939.2012.08.007.
[46]	Um SW, Yoon YS, Lee SM, et al. Predictors of persistent airway stenosis in patients with endobronchial tuberculosis. Int J Tuberc Lung Dis, 2008, 12(1): 57-62. pmid: 18173878
[47]	Jagatia H, Tsolaki AG. The Role of Complement System and the Immune Response to Tuberculosis Infection. Medicina (Kaunas), 2021, 57(2):84. doi:10.3390/medicina57020084.
[48]	Ravesloot-Chavez MM, Van Dis E, Stanley SA. The Innate Immune Response to Mycobacterium tuberculosis Infection. Annu Rev Immunol, 2021, 39:611-637. doi:10.1146/annurev-immunol-093019-010426. pmid: 33637017
[49]	Mi J, Liang Y, Liang J, et al. The Research Progress in Immunotherapy of Tuberculosis. Front Cell Infect Microbiol, 2021, 11:763591. doi:10.3389/fcimb.2021.763591.
[50]	Halliday A, Masonou T, Tolosa-Wright MR, et al. Defining the Role of Cellular Immune Signatures in Diagnostic Evaluation of Suspected Tuberculosis. J Infect Dis, 2022, 225(9): 1632-1641. doi:10.1093/infdis/jiab311.
[51]	Nie W, Wang J, Zeng J, et al. Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China. Infection, 2022, 50(2): 413-421. doi:10.1007/s15010-021-01698-3.
[52]	Shen H, Min R, Tan Q, et al. The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci, 2015, 11(3): 584-590. doi:10.5114/aoms.2015.52362. pmid: 26170852
[53]	Pedral-Sampaio DB, Netto EM, Brites C, et al. Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. Braz J Infect Dis, 2003, 7(4): 245-252. doi:10.1590/s1413-86702003000400004. pmid: 14533985
[54]	Zhang Y, Liu J, Wang Y, et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci, 2012, 55(9): 800-806. doi:10.1007/s11427-012-4368-x.
[55]	Francisco-Cruz A, Mata-Espinosa D, Ramos-Espinosa O, et al. Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis. Tuberculosis (Edinb), 2016, 100:5-14. doi:10.1016/j.tube.2016.05.015.
[56]	Zhang R, Xi X, Wang C, et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis. PLoS One, 2018, 13(7): e0201025. doi:10.1371/journal.pone.0201025.
[57]	Johnson JL, Ssekasanvu E, Okwera A, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med, 2003, 168(2): 185-191. doi:10.1164/rccm.200211-1359OC.
[58]	Sheng L, Li X, Weng F, et al. Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis. J Trop Med, 2022, 2022:5071816. doi:10.1155/2022/5071816.
[59]	中华医学会结核病学分会. 结核病免疫治疗专家共识(2022年版). 中华结核和呼吸杂志, 2022, 45(7): 651-666. doi:10.3760/cma.j.cn112147-20220215-00120.
[60]	Essone PN, Leboueny M, Maloupazoa Siawaya AC, et al. M.tuberculosis infection and antigen specific cytokine response in healthcare workers frequently exposed to tuberculosis. Sci Rep, 2019, 9(1): 8201. doi:10.1038/s41598-019-44294-0.
[61]	Shanmuganathan G, Orujyan D, Narinyan W, et al. Role of Interferons in Mycobacterium tuberculosis Infection. Clin Pract, 2022, 12(5): 788-796. doi:10.3390/clinpract12050082.
[62]	Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet, 1997, 349(9064): 1513-1515. doi:10.1016/S0140-6736(96)12273-X. pmid: 9167461
[63]	Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis, 2004, 4:44. doi:10.1186/1471-2334-4-44.
[64]	Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One, 2009, 4(9): e6984. doi: 10.1371/journal.pone.0006984 URL
[65]	Chin KL, Anis FZ, Sarmiento ME, et al. Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis. J Immunol Res, 2017, 2017:5212910. doi:10.1155/2017/5212910.
[66]	Gong WP, Liang Y, Ling YB, et al. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes. Mil Med Res, 2020, 7(1): 25. doi:10.1186/s40779-020-00258-4.
[67]	全国微卡菌苗临床研究协作组. 母牛分支杆菌菌苗在初治肺结核治疗中的作用. 中华结核和呼吸杂志, 2001, 24(1): 43-47. doi:10.3760/j:issn:1001-0939.2001.01.017.
[68]	陈珣珣, 周琳, 陈志宇, 等. 母牛分枝杆菌菌苗应用于涂阴肺结核超短程治疗方案的临床观察. 广东医科大学学报, 2019, 37(3): 261-264. doi:10.3969/j.issn.1005-4057.2019.03.007.
[69]	丁卫民, 杨俊行, 王光辉. 冻干治疗用母牛分支杆菌菌苗对耐多药肺结核患者临床疗效及细胞免疫功能的影响. 中国临床药理学与治疗学, 2005, 10(5): 559-561. doi:10.3969/j.issn.1009-2501.2005.05.018.
[70]	卢水华, 席秀红, 熊延青. 生物制剂在结核病免疫治疗中的应用. 医药导报, 2010, 29(3): 275-278. doi:10.3870/yydb.2010.03.001.
[71]	陈建强. 乌体林斯对结核性渗出性胸膜炎的辅助治疗意义. 江苏大学学报(医学版), 2003, 13(2): 148-149. doi:10.3969/j.issn.1671-7783.2003.02.031.
[72]	Liang Y, Zhang X, Bai X, et al. Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice. BMC Immunol, 2017, 18(1): 11. doi:10.1186/s12865-017-0196-x.
[73]	Liang Y, Zhang X, Xiao L, et al. Immunogenicity and therapeutic effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis. Curr Gene Ther, 2016.
[74]	Baldwin SL, Reese VA, Larsen SE, et al. Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations. Front Microbiol, 2022, 13:935444. doi:10.3389/fmicb.2022.935444.
[75]	Mir SA, Sharma S. Immunotherapeutic potential of n-terminally formylated ESAT-6 protein in murine tuberculosis. Int J Mycobacteriol, 2022, 11(1): 108-112. doi:10.4103/ijmy.ijmy_39_21. pmid: 35295032
[76]	Lu J, Guo X, Wang C, et al. Therapeutic Effect of Subunit Vaccine AEC/BC 02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model. Vaccines (Basel), 2022, 10(5):825. doi:10.3390/vaccines10050825.
[77]	Karanika S, Gordy JT, Neupane P, et al. An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis. Front Immunol, 2022, 13:972266. doi:10.3389/fimmu.2022.972266.
[78]	Bekele A, Gebreselassie N, Ashenafi S, et al. Daily adjunctive therapy with vitamin D(3) and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia. J Intern Med, 2018, 284(3): 292-306. doi:10.1111/joim.12767. pmid: 29696707
[79]	Rao M, Ligeiro D, Maeurer M. Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis: learning from innovations in immuno-oncology. Curr Opin Pulm Med, 2019, 25(3): 233-241. doi:10.1097/MCP.0000000000000575. pmid: 30883448
[80]	Parida SK, Madansein R, Singh N, et al. Cellular therapy in tuberculosis. Int J Infect Dis, 2015, 32:32-38. doi:10.1016/j.ijid.2015.01.016. pmid: 25809753
[81]	Shen L, Frencher J, Huang D, et al. Immunization of Vgamma2Vdelta 2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates. Proc Natl Acad Sci U S A, 2019, 116(13): 6371-6378. doi:10.1073/pnas.1811380116.
[82]	Introna M. CIK as therapeutic agents against tumors. J Autoimmun, 2017, 85:32-44. doi:10.1016/j.jaut.2017.06.008. pmid: 28679475
[83]	Kaufmann E, Sanz J, Dunn JL, et al. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell, 2018, 172(1-2): 176-190. e119. doi:10.1016/j.cell.2017.12.031. pmid: 29328912
[84]	Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr, 2017, 36(1): 49-64. doi:10.1016/j.clnu.2016.09.004. pmid: 27642056
[85]	Ter Beek L, Alffenaar JC, Bolhuis MS, et al. Tuberculosis-Related Malnutrition: Public Health Implications. J Infect Dis, 2019, 220(2): 340-341. doi:10.1093/infdis/jiz091. pmid: 30835281
[86]	Bhargava A, Chatterjee M, Jain Y, et al. Nutritional status of adult patients with pulmonary tuberculosis in rural central India and its association with mortality. PLoS One, 2013, 8(10):e77979. doi:10.1371/journal.pone.0077979.
[87]	Sinha P, Ponnuraja C, Gupte N, et al. Impact of Undernutrition on Tuberculosis Treatment Outcomes in India: A Multicenter, Prospective, Cohort Analysis. Clin Infect Dis, 2023, 76(8): 1483-1491. doi:10.1093/cid/ciac915.
[88]	Chandrasekaran P, Saravanan N, Bethunaickan R, et al. Malnutrition: Modulator of Immune Responses in Tuberculosis. Front Immunol, 2017, 8:1316. doi:10.3389/fimmu.2017.01316. pmid: 29093710
[89]	Sinha P, Davis J, Saag L, et al. Undernutrition and Tuberculosis: Public Health Implications. J Infect Dis, 2019, 219(9): 1356-1363. doi:10.1093/infdis/jiy675. pmid: 30476125
[90]	Murray JF, Schraufnagel DE, Hopewell PC. Treatment of Tuberculosis. A Historical Perspective. Ann Am Thorac Soc, 2015, 12(12): 1749-1759. doi:10.1513/AnnalsATS.201509-632PS. pmid: 26653188
[91]	Riva MA. From milk to rifampicin and back again: history of failures and successes in the treatment for tuberculosis. J Antibiot (Tokyo), 2014, 67(9): 661-665. doi:10.1038/ja.2014.108.
[92]	Ockenga J, Fuhse K, Chatterjee S, et al. Tuberculosis and malnutrition: The European perspective. Clin Nutr, 2023, 42(4): 486-492. doi:10.1016/j.clnu.2023.01.016. pmid: 36857957
[93]	Abba K, Sudarsanam TD, Grobler L, et al. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev, 2008, (4): CD006086. doi:10.1002/14651858.CD006086.pub4.
[94]	World Healthy Organization. Guideline: Nutritional Care and Support for Patients with Tuberculosis. Geneva: World Healthy Organization, 2013.
[95]	Ockenga J, Grimble R, Jonkers-Schuitema C, et al. ESPEN Guidelines on Enteral Nutrition: Wasting in HIV and other chronic infectious diseases. Clin Nutr, 2006, 25(2): 319-329. doi:10.1016/j.clnu.2006.01.016. pmid: 16698147
[96]	Akkerman OW, Ter Beek L, Centis R, et al. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients. Int J Infect Dis, 2020, 92S:S10-S14. doi:10.1016/j.ijid.2020.01.029. pmid: 31982628
[97]	中华医学会结核病学分会重症专业委员会. 结核病营养治疗专家共识. 中华结核和呼吸杂志, 2020, 43(1): 17-26. doi:10.3760/cma.j.issn.1001-0939.2020.01.006.
[98]	张黎瑛. 肺结核的中医治疗. 家庭医学, 2023 (14): 16-17.
[99]	国家中医药管理局. 中医病证诊断疗效标准:ZY/T 001.1-001.9-94.南京:南京大学出版社, 1994.
[100]	陈林锦, 吴显伟, 张少言, 等. 基于古代医籍和数据挖掘探讨中医辨治肺结核的用药规律. 现代中西医结合杂志, 2023, 32(7): 987-993. doi:10.3969/j.issn.1008-8849.2023.07.025.
[101]	徐红艳, 张燕. 养阴祛瘀方辅助治疗对肺结核患者血清血管内皮生长因子、血清干扰素-γ水平及免疫功能的影响. 世界中西医结合杂志, 2023, 18(1): 148-152. doi:10.13935/j.cnki.sjzx.230125.
[102]	Ma J, Huang M, Wang SH, et al. Undiagnosed pleural effusion treated with traditional Chinese medicine: A case report. Explore (NY), 2022, 18(3): 362-365.
[103]	郭净, 刘忠达, 丰银平, 等. 抗痨合剂改善126例老年肺结核治疗转归的研究. 浙江中医杂志, 2023, 58(1): 10-11. doi:10.3969/j.issn.0411-8421.2023.01.004.
[104]	张震, 李德方, 郑旭鹏. 十全大补汤联合营养支持对胸腔镜肺叶切除术患者肺功能、免疫功能的影响. 中国中医药科技, 2023, 30(3): 571-573.
[105]	闫唯韦, 汪雅锋, 余心琦, 等. 百部芩连汤辅助西药治疗肺结核的疗效观察及对炎性因子和免疫功能的影响. 中国中医药科技, 2023, 30(3): 505-507.
[106]	张金良. 百合固金汤联合常规抗结核方案治疗老年肺结核. 中医学报, 2023, 38(3): 638-643. doi:10.16368/j.issn.1674-8999.2023.03.105.
[107]	梁健, 康文婷, 冯晶, 等. 基于“杀虫、补虚”理论探讨中药对脊柱结核免疫调控机制的研究进展. 中国医药导报, 2023, 20(9): 46-49,57. doi:10.20047/j.issn1673-7210.2023.09.09.
[108]	Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci, 2011, 13(1): 7-23. doi:10.31887/DCNS.2011.13.1/wkaton.
[109]	Oh KH, Choi H, Kim EJ, et al. Depression and risk of tuberculosis: a nationwide population-based cohort study. Int J Tuberc Lung Dis, 2017, 21(7): 804-809. doi:10.5588/ijtld.17.0038. pmid: 28633706
[110]	Lopez AG. Tuberculosis and the severely mentally ill. Am J Psychiatry, 1994, 151(1): 151-152. doi:10.1176/ajp.151.1.151b.
[111]	McQuistion HL, Colson P, Yankowitz R, et al. Tuberculosis infection among people with severe mental illness. Psychiatr Serv, 1997, 48(6): 833-835. doi:10.1176/ps.48.6.833.
[112]	Wang XB, Li XL, Zhang Q, et al. A Survey of Anxiety and Depressive Symptoms in Pulmonary Tuberculosis Patients With and Without Tracheobronchial Tuberculosis. Front Psychiatry, 2018, 9:308. doi:10.3389/fpsyt.2018.00308.
[113]	Sweetland A, Oquendo M, Wickramaratne P, et al. Depression: a silent driver of the global tuberculosis epidemic. World Psychiatry, 2014, 13(3): 325-326. doi:10.1002/wps.20134.
[114]	Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2004, 8(6): 749-759. pmid: 15182146
[115]	Doherty AM, Kelly J, McDonald C, et al. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry, 2013, 35(4): 398-406. doi:10.1016/j.genhosppsych.2013.03.018.
[116]	Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretro-viral and second line anti-TB treatment in Mumbai, India. PLoS One, 2012, 7(7): e40781. doi:10.1371/journal.pone.0040781.
[117]	Trenton AJ, Currier GW. Treatment of Comorbid Tuberculosis and Depression. Prim Care Companion J Clin Psychiatry, 2001, 3(6): 236-243. doi:10.4088/pcc.v03n0610.
[118]	Duarte EC, Bierrenbach AL, Barbosa da Silva J, Jr., et al. Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health, 2009, 63(3): 233-238. doi:10.1136/jech.2008.078972.
[119]	Franke MF, Appleton SC, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis, 2008, 46(12): 1844-1851. doi:10.1086/588292. pmid: 18462099
[120]	Sweetland AC, Kritski A, Oquendo MA, et al. Addressing the tuberculosis-depression syndemic to end the tuberculosis epidemic. Int J Tuberc Lung Dis, 2017, 21(8): 852-861. doi:10.5588/ijtld.16.0584. pmid: 28786792
[121]	Pachi A, Bratis D, Moussas G, et al. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberc Res Treat, 2013, 2013:489865. doi:10.1155/2013/489865.
[122]	Arbex MA, Varella Mde C, Siqueira HR, et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol, 2010, 36(5):626-640. doi:10.1590/s1806-37132010000500016. pmid: 21085830
[123]	Chandra M, Rana P, Chandra K, et al. Tuberculosis-Depression syndemic: A public health challenge. Indian J Tuberc, 2019, 66(1): 197-202. doi:10.1016/j.ijtb.2019.02.007. pmid: 30878069
[124]	Walker IF, Baral SC, Wei X, et al. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders. Int J Tuberc Lung Dis, 2017, 21(6): 603-609. doi:10.5588/ijtld.17.0135. pmid: 28482954
[125]	de la Mora IL, Martinez-Oceguera D, Laniado-Laborin R. Chronic airway obstruction after successful treatment of tuberculosis and its impact on quality of life. Int J Tuberc Lung Dis, 2015, 19(7): 808-810. doi:10.5588/ijtld.14.0983. pmid: 26056106
[126]	Jung JW, Choi JC, Shin JW, et al. Pulmonary Impairment in Tuberculosis Survivors: The Korean National Health and Nutrition Examination Survey 2008—2012. PLoS One, 2015, 10(10):e0141230. doi:10.1371/journal.pone.0141230.
[127]	Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J, 2015, 46(4): 1104-1112. doi:10.1183/13993003.02325-2014. pmid: 26113680
[128]	Vecino M, Pasipanodya JG, Slocum P, et al. Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. J Infect Public Health, 2011, 4(5-6): 244-252. doi:10.1016/j.jiph.2011.08.005.
[129]	Lam KB, Jiang CQ, Jordan RE, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest, 2010, 137(3): 593-600. doi:10.1378/chest.09-1435.
[130]	Visca D, Zampogna E, Sotgiu G, et al. Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. Eur Respir J, 2019, 53(3). doi:10.1183/13993003.02184-2018.
[131]	Hoger S, Lykens K, Beavers SF, et al. Longevity loss among cured tuberculosis patients and the potential value of prevention. Int J Tuberc Lung Dis, 2014, 18(11): 1347-1352. doi:10.5588/ijtld.14.0242. pmid: 25299869
[132]	Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST.
[133]	Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother, 2005, 55(4): 430-435. doi:10.1093/jac/dki027.
[134]	Dailey LA, Schmehl T, Gessler T, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release, 2003, 86(1): 131-144. doi:10.1016/s0168-3659(02)00370-x.
[135]	Rikimaru T. Endobronchial tuberculosis. Expert Rev Anti Infect Ther, 2004, 2(2): 245-251. doi:10.1016/j.ijtb.2015.02.002.
[136]	马艳红. 雾化吸入抗结核药治疗肺结核合并支气管结核病临床分析. 养生大世界, 2021, 10: 180.
[137]	佟勃杉. 药物雾化吸入疗法联合纤支镜介入疗法治疗支气管内膜结核患者的疗效分析. 中国现代医生, 2020, 58(16): 40-42,46. doi:10.19368/j.cnki.2096-1782.2022.19.019.
[138]	Baykan AH, Sayiner HS, Aydin E, et al. Extrapulmonary tuberculosis: an old but resurgent problem. Insights Imaging, 2022, 13(1): 39. doi:10.1186/s13244-022-01172-0.
[139]	Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings. Radiographics, 2019, 39(7): 2023-2037. doi:10.1148/rg.2019190109. pmid: 31697616
[140]	Srivanitchapoom C, Sittitrai P. Nasopharyngeal Tuberculosis: Epidemiology, Mechanism of Infection, Clinical Manifestations, and Management. Int J Otolaryngol, 2016, 2016:4817429. doi:10.1155/2016/4817429.
[141]	张玉琴, 阎少波, 谢燕妮. 异烟肼局部注射治疗颈部淋巴结核的护理. 当代护士(中旬刊), 2021, 28(1): 34-36. doi:10.19792/j.cnki.1006-6411.2021.02.013.
[142]	马青萱, 韦伟, 香亮. 分析针对淋巴结核患者局部使用利福平粉针剂治疗的效果. 健康必读, 2019, 16: 179-180.
[143]	Guo Y, Xu M, Li L, et al. Comparative efficacy of traditional conservative treatment and CT-guided local chemotherapy for mild spinal tuberculosis. BMC Musculoskelet Disord, 2022, 23(1): 589. doi:10.1186/s12891-022-05545-w.
[144]	Yin XH, Zhang HQ, Hu XK, et al. Treatment of pediatric spinal tuberculosis abscess with percutaneous drainage and low-dose local antituberculous therapy: a preliminary report. Childs Nerv Syst, 2015, 31(7): 1149-1155. doi:10.1007/s00381-015-2694-6.
[145]	Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, et al. Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis. J Neurol, 2022, 269(7): 3482-3494. doi:10.1007/s00415-022-11052-8. pmid: 35288778
[146]	李莉. 利奈唑胺联合鞘内注射治疗结核性脑膜炎的效果研究. 健康必读, 2023, 4: 99-100.
[147]	张欣. 异烟肼鞘内注射联合利奈唑胺治疗结核性脑膜炎及对肝功能的影响. 四川生理科学杂志, 2023, 45(6): 1046-1048,1999.
[148]	Nakatani Y, Suto Y, Fukuma K, et al. Intrathecal Isoniazid for Refractory Tuberculous Meningitis with Cerebral Infarction. Intern Med, 2017, 56(8): 953-957. doi:10.2169/internalmedicine.56.6945.
[149]	Li D, Lv P, Lv Y, et al. Magnetic resonance imaging characteristics and treatment aspects of ventricular tuberculosis in adult patients. Acta Radiol, 2017, 58(1): 91-97. doi:10.1177/0284185116633913. pmid: 26936900
[150]	Ashizawa N, Kubo R, Tagawa R, et al. Efficacy of Intrathecal Isoniazid and Steroid Therapy in Refractory Tuberculous Meningitis. Intern Med, 2023. doi:10.2169/internalmedicine.1917-23.